Methods and strains for producing bioproducts in aureobasidium pullulans

ABSTRACT

The present disclosure provides methods for producing bioproducts from novel genetically altered strains of  Aureobasidium pullulans . Methods and materials for the construction of these strains, examination of the bioproducts and analysis and isolation of the bioproducts from genetically altered strains is provided. Genetically altered  A. pullulans  strains in which one or more genes encoding biosynthetic enzymes are knocked out is detailed and the benefits of using such strains described.

CROSS-REFERENCE

The present application is a divisional of application Ser. No.15/212,471, filed on Jul. 18, 2016 and also claims priority to U.S.Provisional Patent Application Ser. No. 62/193,875 filed Jul. 17, 2015,the content of which is expressly incorporated herein by reference.

BACKGROUND OF THE INVENTION Field of Invention

This invention relates to genetically modified strains of Aureobasidiumpullulans that are capable of producing desirable bioproducts. Byaltering the biochemistry of the disclosed strains via geneticmanipulation, strains have been produced that no longer producebio-contaminants such as melanin and melanin-related pigments. Thepresence of such pigments adds significant cost to the production ofbioproducts because they must be removed prior to further processing ofthe desired products. Additionally, some strains described herein aremodified to delete the genes encoding for biosynthetic enzymes thatproduce undesired products. Therefore, modified strains lacking thecapacity of forming less-desired bioproducts have been constructed thatform target bioproducts preferentially on cheaper substrates. Utilizingthese methods and strains, production of desired products can beachieved under more economically feasible conditions, resulting in abenefit to food, pharmaceutical, industrial, biofuel and other importantindustries.

Background

Aureobasidium pullulans is a yeast-like fungus, perhaps best well-knownas the source of the exopolysaccharide pullulan, which iscommercially-produced for numerous consumer and industrial applications,such as emulsifiers, thickeners, and edible films (Leathers,Polysaccharides from eukaryotes. In: Vandamme, E. J., De Baets, S., andSteinbuchel, A., Editors. Biopolymers. Weinheim, Germany: Wiley-VCH. p.1-35 (2002); Singh et al., Carb. Polymers, 73(4):515-31, (2008)). A.pullulans also produces other useful bioproducts, including industrialenzymes (Leathers et al., Biotech Lett., 35(10):1701-6 (2013); Rich etal., Enz. Microb. Tech., 53(1):33-37 (2013); Liu, et al., Anton LeeuwInt. J. G., 94(2):245-55 (2008); Leathers, J. Indus. Microbiol.4(5):341-7 (1989); Kudanga et al., J. Basic Microbiol. 47(2): 138-47(2007)), the biopolyester poly((3-L-malic acid) (Leathers andManitchotpisit, Biotech. Lett., 35(1):83-9 (2013), and numerousbioactive compounds (Wang, et al., Bioresource Tech., 100(9):2639-41(2009); Chi, et al., Appl. Microbiol. Biotech., 82(5):793-804 (2009);Slightom, et al., Gene, 431(1-2):67-79 (2009)), including anextracellular dense “oil” that accumulates on the bottom of thefermentation flask (Nagata, et al., in Biosci. Biotech. Biochem.,57(4):638-42 (1993)). A partial structure of this oil suggested thatthey were 3,5-dihydroxydecanoyl and 5-hydroxy-2-decanoyl esters ofarabitol and mannitol (Kurosawa, et al., Biosci., Biotech. Biochem.,58(11):2057-60 (1994)) and that these polyol lipids exert ananti-proliferative effect on cancer cell lines (Isoda and Nakahara, J.Ferment. Bioeng., 84(5):403-406 (1997)).

Different strains of A. pullulans demonstrate different phenotypes withregards to bioproducts produced and can be genetically distinguishedfrom each other. (Manitchotpisit, et al., Mycol. Res., 133(10):1107-20(1997)). It has been noted that about half of all strains of thisfilamentous fungus produced oils, with certain genetically-relatedstrains showing the highest yields (Id.; Manitchotpisit, et al.,Biotech. Lett., 33(6):1151-57 (2011); Manitchotpisit, et al., World J.Micro. Biotech., 30(8):2199-2204 (2014)). Oil colors range from brightyellow to malachite and more than half of the strains produced oil thatwas fluorescent. Preliminary studies suggest that these pigments arelikely a result of contamination by melanin, melanin breakdown products,and melanin intermediates, which are common pigments associated with A.pullulans. The oils have demonstrated biosurfactant properties(Manitchotpisit, et al. (2011)). Additionally, it has been shown thatoil from different strains differentially inhibits mammalian cancer celllines (Manitchotpisit, et al. (2014)). Recently, these microbial oilshave been demonstrated to exhibit potent selective antibacterialactivities against certain Streptococcal species (Bischoff, et al., J.Antibiot., (2015) 68:642-45).

The antibacterial activities of these microbial oils (also termed“liamocins”) may have potential applications, similar to otherglycolipids or A. pullulans secreted metabolites, as a veterinarytreatment (Cortes-Sanchez, et al., Microbiol. Res., 168(1):22-32(2013)), an antifouling agent (Gao, et al., Marine Poll. Bull.,77(1-2):172-6 (2013); Abdel-Lateff, et al., Nat. Prod. Commns.,4(3):389-94 (2009)), and a phytopathogen control agent (Le Dang, et al.,J. Agr. Food Chem., 62(15):3363-70 (2014)). In addition, themedium-chain dihydroxydecanoate fatty acid is promising as a potentialchemical feedstock for the synthesis of a wide variety of commerciallyrelevant products, such as biosurfactants and polymers (Tang, et al.,Polymer Chem., 5(9):3231-37 (2014); Schneiderman, et al., J. Chem. Edu.,91(1); 131-5 (2014).

A. pullulans is also used for production the antibiotic aureobasidin andβ-glucan. Production of both of these products could be improved byutilizing strains that are no longer producing melanin ormelanin-related pigments. In addition, A. pullulans was recently shownto produce significant amounts of intracellular lipids (Wang et al.,Process Biochem., 49(5):725-31 (2014)), which may have potential forbiodiesel or specialty oil production (Sitepu et al., Biotech. Adv.,32(7):1336-1360 (2014)).

As alluded to above, one of the problems with using A. pullulans forbioproduct formation is that most strains produce darkmelanin-associated pigments that contaminate the final desired product.These contaminating pigments can be removed by treatment with activatedcharcoal or hydrogen peroxide, but further purification withultrafiltration and ion exchange resins are typically required. Theseclean up steps frequently result in loss of the desired bioproduct andadd further cost to the manufacturing process (Mishra and Vuppu, Res. J.Microbiol. Biotech., 2:16-19 (2013); Leathers, Appl. Microbiol.Biotech., 62(5-6):468-473 (2003)). Oils and other bioproducts free ofmelanin or melanin-related pigments would be easier and cheaper topurify, making them more valuable and more economically feasible toproduce. Thus, downstream products, such as biodiesel and food additivesand preservatives would also be cheaper to produce.

Therefore, it is an object of the present invention to provide methodsand strains of A. pullulans for the production of desired bioproducts aswell as melanin-free bioproducts. Using the strains and methodologiespresented here provides not only for a cheaper alternative to the use ofnon-modified strains, but also allows for a more ecologicallyresponsible approach for the production of some bioproducts.

SUMMARY OF THE INVENTION

One aspect of the present invention is providing a biologically purestrain lacking mannitol-1-phosphate-dehydrogenase activity. In oneinstance, the biologically pure strain is the A. pullulans strain MpdKO.

An additional aspect of the invention disclosed herein is providing abiologically pure strain lacking mannitol-dehydrogenase activity. In oneinstance, the biologically pure strain is the A. pullulans strainMdh2KO.

It is another object of the invention disclosed herein to provide abiologically pure strain lacking polyketide-synthase activity. In oneinstance, the biologically pure strain is the A. pullulans strain PksKO.

Further provided herein is a method of producing arabitol-liamocins,comprising the steps of: a) growing a culture of A. pullulans comprisinga biologically pure strain lacking a functional MPD1 gene underconditions sufficient to support the production of arabitol-liamocins,such as growth media having a substantial absence of arabitol; and b)collecting the arabitol-liamocins from at least part of the culture,thereby producing arabitol-liamocins. In some embodiments, thebiologically pure strain is the deposited strain NRRL 67079. In stillother embodiments, the growth medium contains glucose as the sole carbonsource.

An additional embodiment provided herein is a method of producing one ormore bioproducts, comprising the steps of: growing a culture of A.pullulans comprising a biologically pure strain lacking a functionalMDH2 gene and lacking a functional MPD1 gene under conditions sufficientto support the production of one or more bioproducts including liamocinsand exophilins; and collecting one or more of the bioproducts from atleast part of the culture, thereby producing the bioproduct. In someembodiments of this methodology, the growth of the culture occurs in oron a growth medium containing glucose or fructose as the sole carbonsource. In specific embodiments, the bioproduct is an exophilin. Inother embodiments, the bioproduct is a liamocin with a lactose, glucose,mannose, galactose, arabinose, xylose, glucitol, galactitol, xylitol,ribitol, threitol, erythritol, or glycerol head group. In still anotherembodiment, the bioproduct is a fructose-liamocin (a liamocin with afructose head group).

Another invention detailed herein is a method of producing massoialactone from a culture of A. pullulans, comprising the steps of: growinga culture of A. pullulans comprising a biologically pure strain lackinga functional PKS gene under conditions sufficient to support theproduction of massoia lactone; and b) collecting the massoia lactonefrom at least part of the culture, thereby producing massoia lactone. Ina particular embodiment, the biologically pure strain utilized inpracticing this methodology is the deposited strain NRRL 67080.

In yet another embodiment of the invention, this application discloses amethod of producing a substantially melanin-free bioproduct from aculture of A. pullulans, comprising the steps of: a) growing a cultureof A. pullulans comprising a biologically pure strain lacking afunctional PKS4 gene under conditions sufficient to support theproduction of the bioproduct; and b) collecting the bioproduct from atleast part of the culture, thereby producing a substantiallymelanin-free bioproduct. In some instances the bioproduct produced isone or more of pullulan, a liamocin, a lactone, an exophilin,poly(β-malic acid), β-glucan, aureobasidin, an intracellular fatty acid,and a triacylglycerol. In specific embodiments, the bioproduct is aliamocin, such as those with a head group comprised of lactose, glucose,mannose, galactose, arabinose, xylose, glucitol, galactitol, xylitol,ribitol, threitol, erythritol, or glycerol. In other embodiments, thebioproduct is massoia lactone. This methodology can be practiced usingthe biologically pure deposited strain NRRL 67080.

Also provided herein are compositions containing the novelfructose-liamocin (liamocin with a fructose head group). Suchfructose-liamocins can be produced utilizing a biologically pure A.pullulans strain lacking a functional MDH2 gene and lacking a functionalMPD1 gene.

INCORPORATION BY REFERENCE

All publications, patents and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication, patent or patent application wasspecifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

The novel features of the invention are set forth with particularity inthe claims. Features and advantages of the present invention arereferred to in the following detailed description, and the accompanyingdrawings of which:

FIG. 1 provides an example of liamocin structures. Man-A2 (left)contains three 0-linked 3,5-dihydroxydecanoate groups with a mannitolheadgroup. Ara-A2 (right) contains an arabitol headgroup. R═OH orO-acetyl. A2 defines the R group as 0-acetyl.

FIG. 2 provides a proposed biosynthetic pathway for production ofmannitol and arabitol in A. pullulans.

FIG. 3 provides a diagram of DNA constructs used for deletion of the (A)pks4 gene and (B) the mpd1 gene in A. pullulans. The A. pullulans transelongation factor promoter (TEF Prom) was fused to the Escherichia colihygromycin phosphotransferase gene (hph), and the TrypC terminator fromAspergillus nidulans (TrpC Term) obtained from plasmid pCSN43(www.fgsc.net/fgn41/carroll.html). The hygromycin resistant expressioncassette was then flanked with 5′ upstream and 3′ downstream regions ofeither the pks4 or mpd1 genes. Primers used for PCR amplification of DNAfragments are shown with arrows designating the direction of synthesis.Size of the constructs (base pairs) used in our examples is shown at thebottom.

FIG. 4 provides MALDI-TOF spectra of purified liamocins from A.pullulans NRRL 50384 (top) and A. pullulans MpdKO transformant grown onPM medium with 50 g/L glucose.

FIG. 5 provides MALDI-TOF spectra of purified liamocins from A.pullulans NRRL 50384 (top) and A. pullulans MpdKO transformant grown onPM medium with 50 g/L fructose.

FIG. 6 provides a comparison of melanin pigments between cultures of A.pullulans NRRL 50384 (left) and A. pullulans PksKO transformant (right).

FIG. 7 provides a comparison of pigments in liamocins purified from A.pullulans NRRL 50384 (left) and A. pullulans PksKO transformant (right).

FIG. 8 provides MALDI-TOF spectra of purified liamocins from A.pullulans NRRL 50384 (top) and A. pullulans PksKO transformant.

FIG. 9 provides a MALDI-TOF spectrum of purified massoia lactone from A.pullulans PksKO transformant.

FIG. 10 provides MALDI-TOF spectra of purified liamocins from A.pullulans Mdh2KO transformant (top) and A. pullulans Mdh2KO/Mpd1KOtransformant grown on PM medium with 50 g/L glucose.

FIG. 11 provides MALDI-TOF spectra of purified liamocins from A.pullulans Mdh2KO transformant (top) and A. pullulans Mdh2KO/Mpd1KOtransformant grown on PM medium with 50 g/L fructose.

FIG. 12 provides GC profiles (as peracetates) of purified and treatedliamocins from A. pullulans Mdh2.Mpd1KO transformant grown on PM mediumwith 50 g/L fructose.

FIG. 13 provides a generic fructose-liamocin structure in which thefructose head group and the variable R₁ and R₂ groups are indicated.

STATEMENT OF DEPOSIT

Strains representative of the inventions disclosed herein were depositedon Aug. 6, 2015 under the terms of the Budapest Treaty with theAgricultural Research Service (ARS) Patent Culture Collection. Arepresentative A. pullulans Mpd1KO strain (a strain with a disruptedMPD1 gene (SEQ ID NO. 1)) was deposited under ARS Patent CultureCollection Reference No. NRRL 67079 and lacks a functional MPD1 gene. Arepresentative A. pullulans Psk4KO strain (a strain with a disruptedPSK4 gene (SEQ ID NO. 4)) was deposited under ARS Patent CultureCollection Reference No. NRRL 67080 and lacks a functional PSK4 gene.Strains representative of the inventions disclosed herein were alsodeposited on Jul. 12, 2016 under the terms of the Budapest Treaty withthe Agricultural Research Service (ARS) Patent Culture Collection. Arepresentative A. pullulans Mdh2KO/Mpd1KO strain (a strain with adisrupted MPD1 gene (SEQ ID NO. 1) and a disrupted MDH2 gene (SEQ ID NO.3)) was deposited under ARS Patent Culture Collection Reference No. NRRL67281 and lacks a functional MPD1 gene and a functional MDH2 gene. Arepresentative A. pullulans Mdh2KO strain (a strain with a disruptedMDH2 gene (SEQ ID NO. 3) was deposited under ARS Patent CultureCollection Reference No. NRRL 67282 and lacks a functional MDH2 gene.The microorganism deposits were made under the provisions of the“Budapest Treaty on the International Recognition of the Deposit ofMicroorganisms for the Purposes of Patent Procedure”. All restrictionson the availability to the public of these deposited microorganisms willbe irrevocably removed upon issuance of a United States patent based onthis application. For the purposes of this invention, any A. pullulansstrains having the identifying characteristics of NRRL 67079, NRRL67080, NRRL 67281, or NRRL 67282, including subcultures and variantsthereof which have the identifying characteristics and activity asdescribed herein are included.

DETAILED DESCRIPTION OF THE INVENTION

Preferred embodiments of the present invention are shown and describedherein. It will be obvious to those skilled in the art that suchembodiments are provided by way of example only. Numerous variations,changes, and substitutions will occur to those skilled in the artwithout departing from the invention. Various alternatives to theembodiments of the invention described herein may be employed inpracticing the invention. It is intended that the included claims definethe scope of the invention and that methods and structures within thescope of these claims and their equivalents are covered thereby.

Technical and scientific terms used herein have the meanings commonlyunderstood by one of ordinary skill in the art to which the instantinvention pertains, unless otherwise defined. Reference is made hereinto various materials and methodologies known to those of skill in theart. Standard reference works setting forth the general principles ofrecombinant DNA technology include Sambrook et al., “Molecular Cloning:A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press,Plainview, N.Y., 1989; Kaufman et al., eds., “Handbook of Molecular andCellular Methods in Biology and Medicine”, CRC Press, Boca Raton, 1995;and McPherson, ed., “Directed Mutagenesis: A Practical Approach”, IRLPress, Oxford, 1991. Standard reference literature teaching generalmethodologies and principles of fungal genetics useful for selectedaspects of the invention include: Sherman et al. “Laboratory CourseManual Methods in Yeast Genetics”, Cold Spring Harbor Laboratory, ColdSpring Harbor, N.Y., 1986 and Guthrie et al., “Guide to Yeast Geneticsand Molecular Biology”, Academic, New York, 1991.

Any suitable materials and/or methods known to those of skill can beutilized in carrying out the instant invention. Materials and/or methodsfor practicing the instant invention are described. Materials, reagentsand the like to which reference is made in the following description andexamples are obtainable from commercial sources, unless otherwise noted.This invention teaches methods and describes tools for producinggenetically altered strains of A. pullulans.

As used in the specification and claims, use of the singular “a”, “an”,and “the” include plural references unless the context clearly dictatesotherwise.

The term “A. pullulans” refers to Aureobasidium pullulans.

The terms isolated, purified, or biologically pure as used herein, referto material that is substantially or essentially free from componentsthat normally accompany the referenced material in its native state.

The term “about” is defined as plus or minus ten percent of a recitedvalue. For example, about 1.0 g means 0.9 g to 1.1 g.

The phrases “substantially free of melanin,” “substantiallymelanin-free,” or other grammatical variations thereof refer tocultures, media, bioproducts, etc. which contain no detectable melaninproduced by the same microorganism producing a bioproduct of interestprior to any downstream process which would remove melanin. Thesephrases also refer to cultures, media, bioproducts, etc. to whichmelanin is added from an exogenous source, but which otherwise meet thedefinition above.

The phrases “substantially free of arabitol,” “substantiallyarabitol-free,” or other grammatical variations thereof refer tocultures, media, etc., which contain no arabitol, or containinsufficient arabitol (when viewed as a sole carbon source) to supportmore than three doubling times of a microbe producing a desiredbioproduct.

The terms MPD and MPD1 are defined as the gene encodingmannitol-1-phosphate-dehydrogenase in A. pullulans. (SEQ ID NO. 1)

The term MDH1 is defined as the gene encoding a putative mannitoldehydrogenase in A. pullulans that is likely a mitochondrial enzyme(cytochrome) mainly involved in converting mannitol to fructose. (SEQ IDNO. 2)

The term MDH2 is defined as the gene encoding mannitol-dehydrogenase inA. pullulans. (SEQ ID NO. 3)

The terms PKS and PKS4 are defined as the gene encoding polyketidesynthase in A. pullulans. (SEQ ID NO. 4)

The term URA3 is defined as the gene encoding Orotidine-5′-phosphate(OMP) decarboxylase in A. pullulans. (SEQ ID NO. 5)

The terms “MpdKO”, “Mpd1KO”, “Mdh1KO”, “Mdh2KO”, “PksKO”, “Psk4KO”, andgrammatical variations thereof, refer to strains of A. pullulans whichlack the functional indicated gene because of targeted geneticdisruption of the indicated gene. These terms can be used in combinationto refer to strains with multiple disrupted genes, e.g., “Mdh2KO/Mpd1KO”refers to a strain in which both the MDH2 and MPD1 genes have beendisrupted. These terms can also be used to identify the specificgenetically disrupted strains described herein—for example “MpdKO” canrefer to an A. pullulans strain in which the MPD1 gene has beendisrupted with the cassette of SEQ ID NO. 6 and “PksKO” can refer to anA. pullulans strain in which the PKS4 gene has been disrupted with thecassette of SEQ ID NO. 7.

Some embodiments of the present invention involve creating strains whichlack a functional gene. As used herein, the phrase “strains lacking afunctional gene”, and grammatical variations thereof, refers to amicrobial strain in which the referenced gene has been mutated, deleted,or otherwise modified such that the gene no longer produces a functionalprotein. Thus, the phrase includes mutational, insertional anddeletional variants of the subject gene. Such variants can includealteration of transcriptional regulatory machinery, translationalregulatory machinery, coding regions and non-coding regions.Non-limiting examples of such changes include insertion of pointmutations, insertions or deletions causing frame shift mutations,deletions of some or all of the coding sequence, alterations renderingpromoters or start codons inoperable, and alterations rendering stopcodons inoperable. Additionally, introduction of genetic elements thatinterfere with translation, but do not directly affect the target geneitself (e.g., introduction of anti-sense RNA encoding plasmids or othergenetic elements) are also included. Those skilled in the art willreadily recognize methodologies capable of producing strains lacking afunctional gene.

Mutational, insertional, and deletional variants of the disclosednucleotide sequences and genes can be readily prepared by methods whichare well known to those skilled in the art. It is well within the skillof a person trained in this art to make mutational, insertional, anddeletional mutations which are equivalent in function to the specificones disclosed herein.

In some embodiments, strains of A. pullulans are genetically modified todeplete the strain of the capacity to produce a particular biosyntheticenzyme. In other embodiments, strains of A. pullulans are geneticallymodified to deplete the strain of the capacity to produce more than onebiosynthetic enzyme. In some embodiments, depleting the capacity of astrain of A. pullulans to produce one or more biosynthetic enzymesresults in a biochemical alteration in the resulting strain leading toproduction of a desired bioproduct. In still other embodiments,depleting the capacity of a strain of A. pullulans to produce abiosynthetic enzyme prevents that strain from producing an unwanted orundesirable bio-contaminant that would otherwise be co-produced alongwith a desired bioproduct. The discussion below provides techniques thatcan be used to produce genetically modified strains of A. pullulans. Thediscussion is not limiting in any way on the scope of the inventionsdisclosed herein, and any current or future techniques which allow forthe production of such strains by one of skill in the art can beutilized. Following the teachings herein and using knowledge andtechniques well known in the art, the skilled worker will be able tomake a large number of operative embodiments having equivalentfunctionality to those listed and contemplated herein.

Molecular Biological Methods

An isolated nucleic acid is a nucleic acid the structure of which is notidentical to that of any naturally occurring nucleic acid. The termtherefore covers, for example, (a) a DNA which has the sequence of partof a naturally occurring genomic DNA molecule but is not flanked by bothof the coding or noncoding sequences that flank that part of themolecule in the genome of the organism in which it naturally occurs; (b)a nucleic acid incorporated into a vector or into the genomic DNA of aprokaryote or eukaryote in a manner such that the resulting molecule isnot identical to any naturally occurring vector or genomic DNA; (c) aseparate molecule such as a cDNA, a genomic fragment, a fragmentproduced by polymerase chain reaction (PCR), or a restriction fragment;and (d) a recombinant nucleotide sequence that is part of a hybrid gene,i.e., a gene encoding a fusion protein. Specifically excluded from thisdefinition are nucleic acids present in mixtures of (i) DNA molecules,(ii) transformed or transfected cells, and (iii) cell clones, e.g., asthese occur in a DNA library such as a cDNA or genomic DNA library.

The term recombinant nucleic acids refers to polynucleotides which aremade by the combination of two otherwise separated segments of sequenceaccomplished by the artificial manipulation of isolated segments ofpolynucleotides by genetic engineering techniques or by chemicalsynthesis. In so doing one may join together polynucleotide segments ofdesired functions to generate a desired combination of functions.

Recombinant host cells, in the present context, are those which havebeen genetically modified to contain an isolated nucleic molecule of theinstant invention. The nucleic acid can be introduced by any means knownto the art which is appropriate for the particular type of cell,including without limitation, transformation, lipofection,electroporation or any other methodology known by those skilled in theart.

In practicing some embodiments of the invention disclosed herein, it isuseful to modify the genomic DNA of a strain of A. pullulans or anothertarget organism. In many embodiments, such modification involvesdeletion of all or a portion of a target gene, including but not limitedto the open reading frame of the target gene, transcriptional regulatorssuch as promoters of the target gene, and any other regulatory nucleicacid sequences positioned 5′ or 3′ from the open reading frame. Suchdeletional mutations can be achieved using any technique known to thoseof skill in the art. One such approach is to utilize a “deletioncassette” or “knockout cassette” (See, e.g., Fonzi and Irwin, Genetics,134(3):717-28 (1993)). Knockout cassettes typically comprise at leastthree nucleic acid components: 1) an isolated nucleic acid that ishomologous to a 5′ region of a target gene or other locus; 2) anisolated nucleic acid that serves as a marker; and 3) an isolatednucleic acid that his homologous to a 3′region of a target gene or otherlocus. Other genetic elements can be included, depending on theparticular application and design of the cassette. A knockout cassetteis then introduced into an organism of interest via any appropriatemeans known in the art (e.g., electroporation). Taking advantage ofintracellular processes such as homologous recombination, the knockoutcassette integrates into the genome of the target cell. In someinstances, this initial integration event deletes all or part of thetarget gene or locus replacing the wild type genomic DNA and deleting or“knocking out” the wild type DNA between the 5′ and 3′ nucleic acids ofthe knockout cassette. In other instances, the initial integration ofthe knockout cassette is followed by a subsequent recombinatorial eventthat results in the deletion of the target gene or locus, such as byintroducing heterologous DNA flanking the gene or locus of interest andinducing homologous recombination between the two heterologous DNAsegments. Knockout cassettes can be constructed in a variety of waysknown in the art (e.g., split marker transformation). Knockout cassettescan contain multiple markers that allow one skilled in the art to detectinitial integration events and subsequent recombinatorial events.

Where a recombinant nucleic acid is intended for expression, cloning, orreplication of a particular sequence, DNA constructs prepared forintroduction into a prokaryotic or eukaryotic host will typicallycomprise a replication system (i.e. vector) recognized by the host,including the intended DNA fragment encoding the desired polypeptide,and can also include transcription and translational initiationregulatory sequences operably linked to the polypeptide-encodingsegment. Expression systems (expression vectors) may include, forexample, an origin of replication or autonomously replicating sequence(ARS) and expression control sequences, a promoter, an enhancer andnecessary processing information sites, such as ribosome-binding sites,RNA splice sites, polyadenylation sites, transcriptional terminatorsequences, and mRNA stabilizing sequences. Signal peptides may also beincluded where appropriate from secreted polypeptides of the same orrelated species, which allow the protein to cross and/or lodge in cellmembranes or be secreted from the cell.

In some instances, a host cell other than A. pullulans can serve as arecipient for recombinant DNA. For example, a bacterial host may beutilized to clone a plasmid in which a deletion cassette is constructed,replicated, or analyzed. In such instances, a recombinant DNA fragmentmay require an appropriate promoter and other necessary vector sequencesthat can be readily selected so as to be functional in the host.Examples of workable combinations of cell lines and expression vectorsare described in Sambrook et al. (1989) vide infra; Ausubel et al.(Eds.) (1995) Current Protocols in Molecular Biology, Greene Publishingand Wiley Interscience, New York; and Metzger et al. (1988) Nature, 334:31-36. Many useful vectors for expression in bacteria, yeast, fungal,mammalian, insect, plant or other cells are well known in the art andmay be obtained from commercial vendors or constructed de novo.

Knockout cassettes, vectors and other nucleic acids introduced into ahost cell will likely contain a selectable marker, that is, a geneencoding a protein necessary for the survival or growth of a host celltransformed with the nucleic acid. Although such a marker gene may becarried on another polynucleotide sequence co-introduced into the hostcell, it is most often contained on the transforming nucleic acid. Onlythose host cells into which the marker gene has been introduced willsurvive and/or grow under selective conditions. Typical selection genesencode proteins that (a) confer resistance to antibiotics or other toxicsubstances, e.g., hygromycin, ampicillin, neomycin, methotrexate, etc.;(b) complement auxotrophic deficiencies; or (c) supply criticalnutrients not available from complex media. The choice of the properselectable marker will depend on the host cell and appropriate markersfor different hosts are well known in the art.

Selectable markers useful in practicing the methodologies of theinvention disclosed herein can be “positive selectable markers”.Typically, positive selection refers to the case in which a geneticallyaltered cell can survive in the presence of a toxic substance only ifthe recombinant polynucleotide of interest is present within the cell.For example, when a recombinant deletion cassette introduced into a cellcontains a hygromycin B resistance gene, only those transformantscontaining the recombinant polynucleotide will survive when grown in thepresence of hygromycin B. Other positive markers include, but are notlimited to, mutated beta-tubulin (ben) gene, which confers resistance tobenomyl; Bar, which confers resistance to phosphinothricin; Ble, whichconfers resistance to phleomycin; Sat-1, which confers resistance tonourseothricin, and cbx, conferring resistance to carboxin. Genesessential for the synthesis of an essential nutrient (such as amino acidarginine and nucleoside pyrimidine) may also be used as positiveselection markers and are contemplated by the present invention.Negative selectable markers and screenable markers are also well knownin the art and are contemplated by the present invention.

Screening and molecular analysis of recombinant strains of the presentinvention can be performed utilizing nucleic acid hybridizationtechniques. Hybridization procedures are useful for identifyingpolynucleotides, such as those modified using the techniques describedherein, with sufficient homology to the subject regulatory sequences tobe useful as taught herein. The particular hybridization techniques arenot essential to the subject invention. As improvements are made inhybridization techniques, they can be readily applied by one of skill inthe art. Hybridization probes can be labeled with any appropriate labelknown to those of skill in the art. Hybridization conditions and washingconditions, for example temperature and salt concentration, can bealtered to change the stringency of the detection threshold. See, e.g.,Sambrook et al. (1989) vide infra or Ausubel et al. (1995) CurrentProtocols in Molecular Biology, John Wiley & Sons, NY, N.Y., for furtherguidance on hybridization conditions.

Additionally, screening and molecular analysis of genetically alteredstrains, as well as creation of desired isolated nucleic acids can beperformed using Polymerase Chain Reaction (PCR). PCR is a repetitive,enzymatic, primed synthesis of a nucleic acid sequence. This procedureis well known and commonly used by those skilled in this art (seeMullis, U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,800,159; Saiki et al.(1985) Science 230:1350-1354). PCR is based on the enzymaticamplification of a DNA fragment of interest that is flanked by twooligonucleotide primers that hybridize to opposite strands of the targetsequence. The primers are oriented with the 3′ ends pointing towardseach other. Repeated cycles of heat denaturation of the template,annealing of the primers to their complementary sequences, and extensionof the annealed primers with a DNA polymerase result in theamplification of the segment defined by the 5′ ends of the PCR primers.Since the extension product of each primer can serve as a template forthe other primer, each cycle essentially doubles the amount of DNAtemplate produced in the previous cycle. This results in the exponentialaccumulation of the specific target fragment, up to several million-foldin a few hours. By using a thermostable DNA polymerase such as the Taqpolymerase, which is isolated from the thermophilic bacterium Thermusaquaticus, the amplification process can be completely automated. Otherenzymes which can be used are known to those skilled in the art.

Hybridization-based screening of genetically altered strains typicallyutilizes homologous nucleic acid probes with homology to a targetnucleic acid to be detected. The extent of homology between a probe anda target nucleic acid can be varied according to the particularapplication. Homology can be 50%-100%. In some instances, such homologyis greater than 80%, greater than 85%, greater than 90%, or greater than95%. The degree of homology or identity needed for any intended use ofthe sequence(s) is readily identified by one of skill in the art. Asused herein percent sequence identity of two nucleic acids is determinedusing the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci.USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Natl.Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into theNBLAST and XBLAST programs of Altschul et al. (1990) J. Mol. Biol.215:402-410. BLAST nucleotide searches are performed with the NBLASTprogram, score=100, wordlength=12, to obtain nucleotide sequences withthe desired percent sequence identity. To obtain gapped alignments forcomparison purposes, Gapped BLAST is used as described in Altschul etal. (1997) Nucl. Acids. Res. 25:3389-3402. When utilizing BLAST andGapped BLAST programs, the default parameters of the respective programs(NBLAST and XBLAST) are used. See www.ncbi.nih.gov.

Preferred host cells are members of the genus Aureobasidium, especiallyA. pullulans. Filamentous fungi such as members of the generaAspergillus, Trichoderma, Penicillium, etc. are also useful hostorganisms for expression of the DNA of this invention. (Van den Handel,C. et al. (1991) In: Bennett, J. W. and Lasure, L. L. (eds.), More GeneManipulations in Fungi, Academic Press, Inc., New York, 397-428). Yeastssuch as Saccharomyces cerevisiae, Candida albicans, Candida glabrata,and Cryptococcus neoformans, etc. are also useful host organisms.

Microbial Cultures

Aureobasidium pullulans is a ubiquitous fungus commonly found in samplesof soil, water, air and decaying plant material. Isolates of A.pullulans exhibit polymorphic forms ranging from blastic conidia andswollen cells to pseudohyphae, hyphae, and chlamydospores, depending onisolate differences, age, medium and culture conditions (Cooke,Mycopathologia, 12:1-45 (1959); Leathers, Polysaccharides fromeukaryotes. In: Vandamme, E. J., De Baets, S., and Steinbuchel, A.,Editors. Biopolymers. Weinheim, Germany: Wiley-VCH. p. 1-35 (2002)).Most strains produce dark pigments (melanin) and pullulan, anexopolysaccharide that, in older cultures can lead to increased cultureviscosity. Like most fungi, culture conditions under which A. pullulansis grown, affect multiple aspects of the biology of the organism,including morphological form and bioproduct spectrum.

Thus, one of skill in the art will recognize that multiple cultureconditions can be modified in practicing the invention disclosed herein.Non-limiting examples of culture conditions that can be modified duringthe application and practice of the inventions disclosed herein,include: 1) temperature; 2) primary carbon source; 3) oxygenconcentration; 4) primary nitrogen source; 5) pH; 6) mineral and otherion concentration; 7) age/growth phase of culture; 8) organization of anindustrial fermenter; and 9) predominant morphological form. One ofskill in the art will recognize that other culture parameters affectingdesired bioproduct production and bioproduct yield can be modified.

In one aspect of the invention, cultures of A. pullulans strainsdescribed herein can be grown at any temperature that facilitates theproduction of one or more bioproducts. For example, a culture can begrown at a temperature of 15°−30° C., or any whole or partial degreewithin that range, including, but not limited to 15.0° C., 15.5° C.,16.0° C., 16.5° C., 17.0° C., 17.5° C., 18.0° C., 18.5° C., 19.0° C.,19.5° C., 20.0° C., 20.5° C., 21.0° C., 21.5° C., 22.0° C., 22.5° C.,23.0° C., 23.5° C., 24.0° C., 24.5° C., 25.0° C., 25.5° C., 26.0° C.,26.5° C., 27.0° C., 27.5° C., 28.0° C., 28.5° C., 29.0° C., 29.5° C.,and 30.0° C.

In some embodiments, the microbial strains described herein can be grownunder conditions where the pH of the culture facilitates the productionof one or more bioproducts of interest. For example, a culture can begrown in media where the pH is between 5.5 and 8.5, 6.0 and 7.5, or anyvalue within that range, including, but not limited to pH 5.5, 5.6, 5.7,5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1,7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5.One of skill in the art will recognize that a stable pH does not need tobe maintained throughout the entirety of the growth of the strainproducing the bioproduct(s) of interest. Thus, in some embodiments, thepH of a microbial culture of the present invention will vary. In otherembodiments, pH buffers can be added to maintain a relatively stable pHwhere the pH of the culture medium over the life of the culture does notvary from a chosen starting point by more than ±0.5.

In some embodiments, microbial strains of the present invention can begrown in the presence of particular carbon sources. For example, aculture can be grown in the presence of simple carbon sources such as(D- or L-) arabitol, sucrose, fructose, glucose, mannose, galactose,arabinose, arabinose, xylose, mannitol, glucitol, galactitol, xylitol,ribitol, threitol, glycerol, gluconic acid, glucosamine, ormeso-erythritol. Alternately, a culture can be grown in the presence ofcomplex carbon sources such as cellulose, starch, beet molasses, carobpod, cornmeal hydrolysates, corn syrup, fuel ethanol fermentationstillage, grape skin pulp, vegetable oils, peat hydrolysate, hydrolyzedpotato starch, and spent sulfite liquor. Carbon sources that are alsosources for other nutritional requirements, such as nitrogen, can beutilized. For example, media for use in the present invention caninclude amino acids such as aspartate, threonine, lysine, methionine,isoleucine, asparagine, glutamic acid, glutamine, proline, alanine,valine, leucine, tryptophan, tyrosine, phenylalanine and their metabolicintermediates. These lists are non-limiting and it is well within thecapabilities of one of skill in the art to utilize other carbon sourcesin practicing the present invention. Any carbon source can be used aloneor in combination with other carbon sources.

Other nutritional parameters can also be varied, including nitrogensources. Non-limiting examples of nitrogen sources include organicnitrogen sources (e.g., peptone, soybean pomace, yeast extract, foodgravy, malt extract, corn steep liquor and soybean flour) and inorganicnitrogen sources (e.g, urea, ammonium sulfate, ammonium chloride,ammonium phosphate, ammonium carbonate and ammonium nitrate) can beincluded in growth media utilized in the practice of the presentinvention. Phosphate sources such as potassium dihydrogen phosphate,dipotassium hydrogen phosphate and their corresponding sodium-containingsalts can be included in growth media as necessary. Metal and mineralsalts such as salts of zinc, iron, magnesium, manganese, calcium andcopper can be included as needed. Other nutritional supplements, such asvitamins (e.g, biotin, thiamine) can also be included. One of skill inthe art will recognize that varying culture nutritional makeup can beutilized to maximize production of a bioproduct of interest and decreaseproduction of undesired by-products. Any of these nutrients can be usedalone or in combination with any other nutrient.

Nutrients can be added to the culture in any feeding regimen, including,but not limited to high cell-density culture, batch culture, fed-batchculture, constantly-fed-batch culture, exponentially-fed batch culture,continuous culture, or a mixture of these approaches for differentnutrients.

In some instances, the length of time a culture is grown can be modifiedto enhance or begin production of a bioproduct of interest. For example,a culture can be grown for 10-300 hours, or more, or any time pointwithin that range, for example 10, 20, 30, 40, 50, 60, 70, 80, 90, 100,110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240,250, 260, 270, 280, 290, 300 hours, or more before harvesting of abioproduct commences.

Additionally, optimization of bioproduct production can depend ongrowing a culture to a particular point in the life cycle. For example,a culture can be grown to early lag phase, middle lag phase, late lagphase, early exponential phase, mid-exponential phase, late exponentialphase, early stationary phase, mid-stationary phase, or death phase. Insome instances, cultures can be maintained in a growth phase (e.g., byfed-batch culture) in order to maintain a particular growth phase forthe culture.

In other instances, culture conditions can be altered so that onemorphological form of A. pullulans strains utilized to producebioproduct(s) of interest predominates over other morphological forms.For example, culture conditions can be controlled so that yeast-likeforms predominate, chlamydospores predominate, or hyphae/pseudohyphaepredominate.

A. pullulans demonstrates strain-specific differences in bioproductproduction and bioproduct production levels. Thus, in practicing themethodologies taught herein, a strain can be selected that alreadyproduces a bioproduct of interest, or produces a bioproduct of interestat a relatively higher level than other strains. One of skill in the artwould be able to utilize the genetic alteration techniques describedherein to produce an altered A. pullulans strain of differinggenotypic/phenotypic backgrounds. Additionally, the approaches providedherein can be utilized to produce genetically altered species of thegenus Aureobasidium other than A. pullulans that produce bioproducts ofinterest.

Bioproduct Extraction from Cultures

To utilize a bioproduct for downstream purposes (e.g., biofuelproduction or for use as a food additive), it may be necessary toextract the bioproduct of interest from the microbial culture. Giventhat bioproducts can comprise different chemical compounds with varyingchemical properties, one of skill in the art will recognize thatdifferent approaches to isolate or purify a bioproduct from a microbialculture will necessarily need to be appropriate for that bioproduct.

A. pullulans produces numerous important bioproducts, including, but notlimited to liamocins, pullulan, poly (β-malic acid), β-glucan,aureobasidin, and intracellular fatty acids or triacylglycerols.Although not all of these products are produced by every strain, many ofthese products are synthesized by A. pullulans NRRL 50384, however, theinvention disclosed herein could be utilized with numerous othermicroorganisms as previously described. The technology for producing andisolating most Aureobasidium bioproducts are fairly well established,but alternative purification methods can be used depending on thedesired applications. One of skill in the art will recognize that thefollowing examples of extraction methodologies are provided as examplesand are not meant to be limiting on the procedures that can be utilizedto practice the invention disclosed herein.

Pullulan and poly(β-L-malic acid) (PMA) are predominantly extracellularand isolated from cell-free culture supernatants. Pullulan and PMA arewater soluble, thus are typically isolated from cultures by collectingsupernatants and precipitating the bioproducts. One approach toisolating these products was described by Manitchotpisit et al. (ibid.,2012). Cells were removed by centrifugation at 10,000×g for 20 min. Theculture supernatants were adjusted to pH 5.0 by the dropwise addition of30% (w/v) CaCO₃. Pullulan was precipitated by the addition of one volumeof 95% ethanol followed by centrifugation at 16,900×g for 30 min. PMAwas then precipitated by the addition of an additional volume of 95%ethanol, followed by incubation at 4° C. overnight and centrifugation at16,900×g for 30 min. Precipitated PMA was dissolved in 200 mL ofpurified water and lyophilized. Any other isolation methodologyappropriate for these bioproducts can be utilized.

Liamocins are typically extracellular and can be separated bycentrifugation and purified through solvent extraction. The followingexample is from Manitchotpisit et al. (ibid. 2011). Approximately 50 mlof cells and heavy oil were removed by centrifugation at 10,000×g for 20min. Extracellular heavy oil appeared as a layer beneath theprecipitated cells. Cells were gently resuspended in 3-5 ml of distilledwater and transferred to a screw-cap glass tube (13 mm×100 mm). Cultureflasks and centrifuge bottles were washed with 3-5 ml of methyl ethylketone and heavy oil was dissolved in this solvent. The dissolved oilwas recombined with the resuspended cells and the mixture was vortexedvigorously and allowed to separate overnight at room temperature. Theaqueous and extracted cell layers were then removed, and the solvent wasevaporated from the oil overnight under a stream of air. Alternatively,whole cultures were extracted with at least 50 ml of methyl ethylketone, and solvent, aqueous, and biomass layers were isolated in aseparatory funnel. The whole culture method is simpler but requires moresolvent and more time for solvent evaporation.

A number of studies describe additional (non-pullulan) polysaccharides,typically water-soluble extracellular polysaccharides, including certainβ-glucans, from certain strains and mutants of A. pullulans (Leathers,Polysaccharides from eukaryotes. In: Vandamme, E. J., De Baets, S., andSteinbuchel, A., Editors. Biopolymers. Weinheim, Germany: Wiley-VCH. p.1-35 (2002)). A typical purification of β-glucans can involve removingcells by centrifugation or filtration, removing contaminants byadsorption with activated carbon, concentrating polysaccharides byultrafiltration, and precipitating final product with 80% ethanol(Muramatsu, et al., PLoS One, 7:(2012)).

Aureobasidins are typically extracellular and purified from afermentation broth through solvent extraction and column purification. Atypical purification could involve solubilizing aureobasidins infermentation broth with an equal volume of ethanol, separating on anadsorption column (e.g., a Diaion HP-40 column) equilibrated with 50%ethanol and eluted with 95% ethanol, diluting elute twice with water andfurther separating on reverse phase ODS-W (Soken ODS-W from SokenChemicals Co.) equilibrated with 40% ethanol and eluted with 60% ethanol(Yoshikawa, et al., J. Antibiotics (Tokyo), 46:1347-54 (1993)).

Triacylglycerol or triglycerides are typically intracellular and removedfrom cells through solvent extraction. A number of different solventextraction methods allow preferential solubilization of the desiredlipid (Christie, Advances in Lipid Methodology, 5:97-115 (2003)). Thesesolvent extraction methods can be utilized with dried (i.e.,lyophilized, oven) cultures or cells that have been lysed throughmechanical, chemical, or enzymatic processes (Yu, et al., Eur. J LipidSci. Tech., 117:730-737 (2015)). A typical extraction method for A.pullulans would involve collecting cells through centrifugation, washingwith saline, drying at 80° C., and homogenizing cells with 2:1chloroform-methanol mixture.

Massoia lactone production by A. pullulans has never been reported ordemonstrated prior to our construction of a strain lacking a functionalPKS gene. During analysis of that knockout strain, we discovered thatmassoia lactone can be found in the extracellular liamocin fractions andintracellularly for A. pullulans. Massoia lactone can be separateddirectly from liamocins by butan-2-one:chloroform:water (1:2:2 byvolume) partitioning. Alternatively, massoia lactone can be extractedfrom lysed cells of this knockout strain using chloroform:methanol (1:1)or acetone:ethyl acetate (1:1), but further purification is required.

Bioproducts and Uses

In practicing the present invention, it will be recognized by one ofskill in the art that any of the disclosed strains can be utilized toproduce a bioproduct of interest. In some instances, an A. pullulansstrain lacking at least one gene encoding a mannitol biosynthetic enzyme(See, FIG. 2) can be utilized to produce a bioproduct of interest. Insome embodiments, the present invention can be practiced using an A.pullulans strain lacking a functionalmannitol-1-phosphate-dehydrogenase-encoding (MPD1) gene (SEQ ID NO. 1)to produce a bioproduct of interest. In another embodiment, the presentinvention can be practiced using an A. pullulans strain lacking afunctional mannitol-dehydrogenase-encoding (MDH2) gene (SEQ ID NO. 3) toproduce a bioproduct of interest. In another embodiment, the presentinvention can be practiced using an A. pullulans strain lacking afunctional polyketide-synthase-encoding (PKS) gene (SEQ ID NO. 4) toproduce a bioproduct of interest. In some embodiments, the presentinvention can be practiced using an A. pullulans strain lacking afunctional putative-mannitol-dehydrogenase-encoding (MDH1) gene (SEQ IDNO. 2) to produce a bioproduct of interest. In still another embodiment,the present invention can be practiced using an A. pullulans strainlacking a functional MPD1 gene and lacking a functional PKS gene toproduce a bioproduct of interest. In still another embodiment, thepresent invention can be practiced using an A. pullulans strain lackinga functional MDH2 gene as well as lacking a functional PKS gene toproduce a bioproduct of interest, while not producing melanin. In stillanother embodiment, the present invention can be practiced using an A.pullulans strain lacking a functional MPD1 gene, lacking a functionalMDH2 gene, and lacking a functional PKS gene to produce a bioproduct ofinterest, while not producing melanin. In particular embodiments, one ofthe strains described in the Examples section can be utilized to producea bioproduct of interest. In other embodiments, the present inventioncan be practiced using an A. pullulans strain lacking a functional copyof a combination of any or all genes (MDH1, MDH2, MPD1, PKS) describedherein.

Liamocins

Experiments utilizing Matrix-Assisted Laser Desorption/Ionization MassSpectrometry (MALDI-TOF MS) spectra suggested that extracellular oilproduced by A. pullulans oil contained a family of related oilstructures. The structure of several of the oil components (termed“liamocins”) from A. pullulans strain NRRL 50380 have previously beenelucidated (Price et al., Carbohyd. Res., 370:24-32 (2013)). Theliamocins identified to date are comprised of a polyol head group(either mannitol, arabitol, or glycerol) that is ester-linked at one endto a highly unusual fatty acid, 3,5-dihydroxydecanoic acid (FIG. 1).These 3,5-dihydroxydecanoic acid groups are themselves joined by1,5-linked ester bonds, so that the liamocins form either A, B, orC-type that contain three, four, or five 3,5-dihydroxydecanoic acidgroups, respectively. In addition, some liamocins contain a single3′-O-acetyl group at the free 3-hydroxy position on the3,5-dihydroxydecanoic fatty acid chain. Liamocins A1 and B1 arenon-acetylated, whereas A2 and B2 each contain a single acetyl group.

Analysis of numerous liamocin-producing A. pullulans isolates grownunder varying conditions reveal that liamocin trimers with a mannitolheadgroup (e.g., Man-A1, Man-A2) are usually the predominant structurewhen glucose, fructose, sucrose, or xylose are used as the carbonsource. Some A. pullulans strains have been identified that producedliamocins that were approximately 40% arabitol-containing structure(e.g., Ara-A1, Ara-A2, Ara-B1) when grown on glucose. Prior to theinventions disclosed herein, however, 100% arabitol-containing liamocinstructures could only be produced by growing cells using arabitol as thesole carbon source. This method likely would be cost-prohibitive formany applications because of the relative expense of arabitol comparedwith glucose. Additionally, separating mixed liamocin structures (e.g.,combinations of mannitol-liamocin and arabitol-liamocin) is technicallyvery difficult. Thus, the strains and methodologies disclosed hereinthat modify the synthesis and/or accumulation of intracellular polyolsin genetically altered Aureobasidium strains of the present inventionwould be valuable as a method to alter the chemical structures of theliamocins and to decrease unwanted polyol synthesis as contaminants ofother bioproducts of interest.

Thus, in one embodiment, arabitol-liamocins can be produced utilizing anA. pullulans strain of the invention when grown in the absence ofarabitol as a carbon source. In some embodiments, the A. pullulansstrain utilized to produce arabitol-liamocins lacks at least one gene ina mannitol biosynthetic pathway. In other embodiments, an A. pullulansstrain lacking a functional gene encoding mannitol-1-phosphatedehydrogenase (MPD1) has been is utilized to produce arabitol-liamocins.In still another embodiment, an A. pullulans strain lacking a functionalMPD1 gene and lacking a functional MDH2 gene is utilized to producearabitol-liamocins.

For example, any strains lacking one or more genes encoding for anyprotein necessary for mannitol production can be grown in the presenceof D-fructose, D-glucose, D-mannose, D-galactose, D-arabinose,L-arabinose, D-xylose, D-mannitol, D-glucitol, D-galactitol, D-xylitol,D-ribitol, D-threitol, L-threitol, D-glycerol, or meso-erythritol. Oneof skill in the art will recognize that this list of carbon sources isnot exclusive and that any carbon source that results in production ofthe desired bioproduct can be utilized. In a particular embodiment, theinexpensive carbon source, D-glucose can be utilized to producearabitol-liamocins utilizing any the strains of this invention. Inanother particular embodiment, arabitol-liamocins are produced utilizingany of the knockout strains described in the Examples below.

In still other embodiments of the present invention, A. pullulansstrains lacking at least one gene encoding a mannitol biosyntheticenzyme as well as lacking a gene encoding polyketide synthase (PKS) areused to produce liamocins that are melanin-free. In one embodiment, astrain used to produce melanin-free liamocins lacks a functional MPD1gene and lacks a functional PKS gene. In another embodiment, a strainused to produce melanin-free liamocins lacks a functional MDH2 gene andlacks a functional PKS gene. In still another embodiment, a strain usedto produce melanin-free liamocins lacks a functional MPD1 gene, lacks afunctional MDH2 gene, and lacks a functional PKS gene. In particularembodiments, a specific strain described in the Examples below can beutilized to produce arabitol-liamocins that are essentially free ofmelanin without the need to remove melanin.

The strains described herein comprising one or more genetic alterationscan be used to produce a desired liamocin. In one embodiment, D- and/orL-mannitol liamocin A1, D- and/or L-mannitol liamocin A2, D- and/orL-mannitol liamocin B1, D- and/or L-mannitol liamocin B2, D- and/orL-mannitol liamocin C1, or D- and/or L-mannitol liamocin C2, or acombination thereof, can be produced as a bioproduct utilizing thestrains of this invention. In another embodiment, D- and/or L-arabitolliamocin A1, D- and/or L-arabitol liamocin A2, D- and/or L-arabitolliamocin B1, D- and/or L-arabitol liamocin B2, D- and/or L-arabitolliamocin C1, or D- and/or L-arabitol liamocin C2, or a combinationthereof, can be produced as a bioproduct utilizing the strains of thisinvention. In a third embodiment, 2-amino-D-mannitol liamocin A1,2-amino-D-mannitol liamocin A2, 2-amino-D-mannitol liamocin B1,2-amino-D-mannitol liamocin B2, 2-amino-D-mannitol liamocin C1, or2-amino-D-mannitol liamocin C2, or a combination thereof, can beproduced as a bioproduct utilizing the strains of this invention. In afourth embodiment, 2-N-acetylamino-D-mannitol liamocin A1,2-N-acetylamino-D-mannitol liamocin A2, 2-N-acetylamino-D-mannitolliamocin B1, 2-N-acetylamino-D-mannitol liamocin B2,2-N-acetylamino-D-mannitol liamocin C1, or 2-N-acetylamino-D-mannitolliamocin C2, or a combination thereof, can be produced as a bioproductutilizing the strains of this invention. In a fifth embodiment,D-fucitol liamocin A1, D-fucitol liamocin A2, D-fucitol liamocin B1,D-fucitol liamocin B2, D-fucitol liamocin C1, or D-fucitol liamocin C2,or a combination thereof can be used as the antibacterial compound ofthis invention. In a sixth embodiment, L-rhamnitol liamocin A1,L-rhamnitol liamocin A2, L-rhamnitol liamocin B1, L-rhamnitol liamocinB2, L-rhamnitol liamocin C1, L-rhamnitol liamocin C2, or a combinationthereof can be produced as a bioproduct utilizing the strains of thisinvention. In a seventh embodiment, L-glycerol liamocin A1, L-glycerolliamocin A2, L-glycerol liamocin B1, L-glycerol liamocin B2, L-glycerolliamocin C1, L-glycerol liamocin C2, D-glycerol liamocin A1, D-glycerolliamocin A2, D-glycerol liamocin B1, D-glycerol liamocin B2, D-glycerolliamocin C1, D-glycerol liamocin C2, L-threitol liamocin A1, L-threitolliamocin A2, L-threitol liamocin B1, L-threitol liamocin B2, L-threitolliamocin C1, L-threitol liamocin C2, D-threitol liamocin A1, D-threitolliamocin A2, D-threitol liamocin B1, D-threitol liamocin B2, D-threitolliamocin C2, L-erythritol liamocin A1, L-erythritol liamocin A2,L-erythritol liamocin B1, L-erythritol liamocin B2, L-erythritolliamocin C1, L-erythritol liamocin C2, D-erythritol liamocin A1,D-erythritol liamocin A1, D-erythritol liamocin B1, D-erythritolliamocin B2, D-erythritol liamocin C1, D-erythritol liamocin C2, or acombination thereof can be produced as a bioproduct utilizing thestrains of this invention. In still another embodiment, a fructoseliamocin (FIG. 13) and exophilins can be produced by a strain of thepresent invention lacking functional MPD1 and MDH1 genes. In yet anotherembodiment, any combination of any of the compounds (glycerol-liamocins,threitol-liamoicins, erythritol-liamocins, mannitol-liamocins,arabitol-liamocins, 2-amino-D-mannitol liamocins,2-N-acetylamino-D-mannitol liamocins, D-fucitol liamocins,fructose-liamocins and L-rhamnitol liamocins) mentioned in thisparagraph can be produced as a bioproduct utilizing the strains of thisinvention.

In another embodiment, a liamocin produced is any of the compoundsdescribed in Formula 1 where R₁ is either, independently, COCH₃ or H;and R₂ is, independently, one or more O-linked 3,5-dihydroxy-decanoategroups; and R₃ is, independently, C_(x)O_(x)H_(2x+1), such as one of thefollowing: L- or D-glycerol, L- or D-threitol, L- or D-erythritol, L- orD-arabitol, L- or D-xylitol, L- or D-lyxitol, L- or D-ribitol, L- orD-allitol, L- or D-altritol, L- or D-mannitol, L- or D-iditol, L- orD-gulitol, L- or D-glucitol (also called sorbitol), L- or D-galactitol(also called dulcitol), L- or D-talitol, 2-amino-D-mannitol,2N-acetylamino-D-mannitol, L-rhamnitol, or D-fucitol; individually or incombination with each other, can be produced as a bioproduct utilizingthe strains of this invention. In still another embodiment, any or allof the above liamocins can be produced as a bioproduct by a strain ofthis invention that lacks the ability to produce melanin. Thus, in suchembodiments, liamocins that are essentially free of melanin are producedby growing strains lacking a functional PKS gene under conditionssufficient to produce the desired liamocin. In a particular embodiment,a desired liamocin is produced by a PKS knockout strain produced by themethods described in the Examples below.

Pullulan

A well-established product of A. pullulans is the exopolysaccharide,pullulan. This complex polysaccharide is a linear homopolysaccharide ofglucose that is often described as an α-(1→6) linked polymer ofmaltotriose subunits, however, other structures (such as the tetramermaltotetraose) may be present within a pullulan polymeric chain(Leathers, Polysaccharides from eukaryotes. In: Vandamme, E. J., DeBaets, S., and Steinbuchel, A., Editors. Biopolymers. Weinheim, Germany:Wiley-VCH. p. 1-35 (2002)). Regular alternation of the (1→4) and (1→6)bonds results in two distinctive properties of this large molecule,namely, structural flexibility and enhanced solubility (Leathers, 1993).Pullulan also demonstrates adhesive properties and a capacity to formfibers, compression moldings and strong, oxygen-impermeable films.Chemical derivatization utilizing reactive groups can be used to alterthe solubility (and other physiochemical properties) of pullulan.Pullulan is non-toxic, edible, and biodegradable, making it useful in awide variety of industrial applications, pharmaceutical applications andfood applications.

Pullulan is considered a dietary fiber in humans and provides fewcalories because it is resistant to mammalian amylases. Some studiesindicate that it functions as a prebiotic, promoting the growth ofbeneficial bacteria. Pullulan can be incorporated in both solid andliquid foods, where it functions to achieve desired consistency,dispersability, moisture retention, and other parameters. It can be usedas a replacement for starch in multiple food applications. It can alsoserve as a food preservative, as pullulan is not readily assimilated bythe bacteria and fungi responsible for food spoilage. It has adhesiveproperties, making it useful as a binder and stabilizer in food pastes.

Films made of pullulan are clear, oxygen-permeable and dissolve readilyin water, thus, these films readily melt in the mouth. One of theprimary uses of such films is in the oral care industry, where pullulanfilm is impregnated with mouthwash or other oral hygiene products.Pullulan films can also be used as coating or packaging material fordried foods, or applied directly to food as a protective coating.

In the pharmaceutical industry, pullulan can be used as a coating orlayer for tablets, pills, and granules. It can be utilized as both acoating in slow-release formulations as well as a preservative toprevent color and taste changes. Pullulan also shows promise as aconjugate for vaccines and can be used as a blood plasma expander inplace of dextran.

Pullulan finds use in the cosmetics industry because it is non-toxic andnon-irritating to the human body. Eye cosmetics, lotions and shampoos,as well as powders, facial packs, hair dressings and tooth powders canall contain pullulan.

Pullulan can also be formed into fibers that resemble nylon or rayon.Pullulan that is compressed or extruded can be formed into materialsthat resemble polystyrene or polyvinyl alcohol. Pullulan also hasapplications in a wide variety of industries, from making paint andelectronics components to paper production and use as a flocculatingagent.

However, pullulan is expensive to make, despite its ecological benefitsover petroleum products. One impediment to producing pullulan is theneed to extract melanin and melanin-related pigments which contaminatecultures of A. pullulans. Thus, one object of the present invention isto provide A. pullulans strains that make pullulan more economicallyfeasible by, for example, bypassing the step of removing melanin, whichadds extra time and expense to the pullulan production process.

In one embodiment, the present invention provides a method of producingmelanin-free pullulan directly in cultures of A. pullulans. Thisembodiment can be achieved by utilizing a strain lacking a functionalPKS gene. In a particular embodiment, production of melanin-freepullulan directly in a culture is achieved using a strain specificallydisclosed in the Examples section below.

Massoia Lactone

Massoia lactone is an alkyl lactone derived from the bark of the Massoiatree (Cryptocaria massoia) found in Papua, Indonesia. Massoia lactone isa popular natural coconut flavoring ingredient, but harvesting andextracting this compound from the bark of the Massoia tree is anexpensive process that results in death of the tree. Consequently, mostmassoia lactone is synthetically produced from petroleum-basedprecursors, despite consumer and producer preferences for naturalproducts (Harbindu and Kumar, Synthesis (12):1954-59 (2011). Prior toconstruction of the PksKO strain described herein, there has never beena report or other description of a massoia-lactone-producing strain ofA. pullulans. Thus, we describe herein an invention allowing theproduction of massoia lactone by A. pullulans. A. pullulans represents apotential alternative source of massoia lactone that is natural,renewable, and environmentally friendly. In addition, we anticipate thatthe market size of massoia lactone could increase significantly if weare able to reduce the cost through fermentative production. Inaddition, there may be other potential applications of using massoia asan anti-bitter agent for artificial sweeteners (Putter and Wonschik, PCTPub. No. WO2013079187) and also an oxygenate fuel additive (Robinson,US. Pub. No. US20060096158A1).

Production of massoia lactone by Aureobasidium species, including A.pullulans, has not been previously described. Thus, one embodiment ofthe present invention is a massoia-lactone-producing strain of A.pullulans. Another embodiment of the present invention is a strain of A.pullulans that lacks a functional PKS gene. Still another embodiment ofthe present invention is a massoia-lactone-producing strain of A.pullulans that lacks a functional PKS gene and also lacks one or moreof: a functional MPD1 gene, a functional MDH2 gene, and a functionalMDH1 gene.

Other Bioproducts

One of skill in the art will recognize that the strains of A. pullulansdescribed herein can be used to produce a bioproduct of interest. Insome embodiments, the bioproduct produced utilizing the strains andmethods of the present invention is a liamocin, pullulan or massoialactone. In other embodiments, the bioproduct produced utilizing thestrains and methods of the present invention is poly (β-malic acid),β-glucan, aureobasidin, a lactone, an intracellular fatty acid ortriacylglycerol. In still other embodiments, a strain of A. pullulansthat lacks a functional PKS gene and is grown under conditionssufficient to produce one or more melanin-free bioproducts, includingbut not limited to a liamocin, pullulan, massoia lactone and otherlactones, poly (β-malic acid), β-glucan, aureobasidin, an intracellularfatty acid and triacylglycerol.

Products

The present invention further provides a medicament, nutritional orpharmaceutical composition comprising any of the bioproducts produced bya genetically altered strain of the present invention. Thesecompositions can be administered in various ways suitable for therapyand can be administered alone or as an active ingredient in combinationwith pharmaceutically acceptable carriers, diluents, adjuvants, andvehicles. Conventional methods such as administering the compounds astablets, suspensions, solutions, emulsions, capsules, powders, syrups,and the like are usable. Known techniques to deliver the compositionsorally or intravenously and retain biological activity are preferred.Formulations that can be administered subcutaneously, topically, orparenterally or intrathecal and infusion techniques are alsocontemplated by the present invention as well as suppositories andimplants.

Pharmaceutically acceptable carriers, diluents, adjuvants and vehiclesas well as implant carriers generally refer to inert, non-toxic solid orliquid fillers, diluents, or encapsulating material not reacting withthe active ingredients of the invention. The pharmaceutical formulationssuitable for injection include sterile aqueous solutions or dispersionsand sterile powders for reconstitution into sterile injectable solutionsor dispersions. The carrier can be a solvent or dispersing mediumcontaining for example, water, ethanol, polyol such as glycerolpropylene glycol, liquid polyethylene glycol, etc., and suitablemixtures thereof and vegetable oils.

Proper fluidity can be maintained by the use of a coating such aslecithin, by the maintenance of the required particle size in the caseof dispersion and by the use of surfactants. Nonaqueous vehicles such ascottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunfloweroil, or peanut oil and esters, such as isopropyl myristate, may also beused as solvents for compound compositions. Additionally variousadditives which enhance the stability, sterility, and isotonicity of thecompositions, including antimicrobial preservatives, antioxidants,chelating agents, and buffers, can be added. Prevention of the action ofmicroorganisms can be ensured by various antibacterial and antifungalagents, for example, parabens, chlorobutanol, phenol, sorbic acid, etc.It may be desirable to include isotonic agents, for example sugars,sodium chloride, etc. Prolonged absorption of the injectablepharmaceutical form can be brought about by the use of agents delayingabsorption, for example, aluminum monostearate, gelatin, etc. Anyvehicle, diluents or additive used would have to be compatible with theanti-microbial adhesion fraction A6 of the invention. The choice ofdelivery system is well within the ordinary skill in the art.

Having described the invention in general, below are examplesillustrating the generation and efficacy of the invention. Neither theexamples, nor the general description above should be construed aslimiting the scope of the invention.

EXAMPLES Example 1

A hygromycin expression cassette used in these transformations wasconstructed by fusing an A. pullulans trans-elongation factor (TEF)promoter to an Escherichi coli hygromycin phosphotransferase gene. Thiswas accomplished by PCR amplification of the TEF promoter usingdegenerate oligonucleotides ApTEF-F and ApTEF-R (Table 1); and A.pullulans NRRL 50383 (RSU6) DNA as template. The product was then clonedinto pCR2.1 (Invitrogen) and further modified by PCR amplification withprimers ApTEF-Sal1 and ApTEF-EcoRV in order to introduce restrictionendonuclease sites. Plasmid pCSN43 was also modified by removing the 0.3kb Xbal fragment and re-ligating the remaining 5.0 kb plasmid in orderto shorten the A. nidulans TrpC terminator and remove an adjacent Cla1site within the polylinker. The A. nidulans TrpC promoter was thenremoved from this resultant plasmid by cutting with Cla1, blunting therestriction endonuclease overhangs, and then digesting with Sal1. Thislinear fragment was then ligated to the modified TEF promoter fragmentdigested with Sal1 and EcoV. Lastly, this modified plasmid was used astemplate for PCR amplification with primers TEF-Hyg-P1 and TEF-Hyg-P2.This 2.5 kb hygromycin resistance cassette was used for all furtherplasmid constructs.

TABLE 1 Primers SEQ Primer ID name Sequence 5′ → 3′ NO. ApTEF-F (GGCTAGRYGCRCGAYTATYCAC 8 ApTEF-R GTTGACGGTKRTGTATGGAAG 9 ApTEF-SalIGCAGGTCGACGGCTAGGCGCGCGATTATTC 10 ApTEF-EcoRVGCAGGATATCTTGACGGTTGTGTATGGAAGATTGAG 11 TEF-Hyg-P1 CGGCTAGGCGCGCGATTATTC12 TEF-Hyg-P2 CGGCCGGCGTATTGGGTGTTA 13 pUC18-P1CGTAATCATGGTCATAGCTGTTTCC 14 pUC18-P2 GCACTGGCCGTCGTTTTACAA 15 Mpd-P1GibGTCACGACGTTGTAAAACGACGGCCAGTGCGACCCG 16 CCGCTCTTTGACCTACAG Mpd-P2GibGCTGTGAATAATCGCGCGCCTAGCCGGGAGGGGAAC 17 AAAGCCATCACACC Mpd-P3GibGCTCCGTAACACCCAATACGCCGGCCGGCGTGTCGG 18 TCGTGCTCCTCTC Mpd-P4GibCACACAGGAAACAGCTATGACCATGATTACGTTGTG 19 GGGCTTTGGAATCTGTGGA Mpd-P5GCGGCAACATCGGTCGTGG 20 Mpd-P6 CATTCCTTGCCGCGGTTGTAG 21 Mpd-P7TCAAGCGCCAAGGTTATCGGTCTG 22 Hyg-P11 GCCGCTTTCCCTCCCATTCC 23 Mpd-P8GTGGCGACGATGGAGGCTTCT 24 Hyg-P13 AGCCCCTGGGTTCGCAAAGATAAT 25 PKS4-P1GibGTCACGACGTTGTAAAACGACGGCCAGTGCGGCTTT 26 GGGCGCATACCGAGAG PKS4-P2GibGCTGTGAATAATCGCGCGCCTAGCCGGCTGAAGGCC 27 AGCACATCCAACT PKS4-P3GibGCTCCGTAACACCCAATACGCCGGCCGGTCGGCCAG 28 CGCATCCTCGTAT PKS4-P4GibCACACAGGAAACAGCTATGACCATGATTACGGCTTC 29 CTCCTGCTGCCAACACTC PKS4-P5TCAGGGCCGATGTTAGGGATGCT 30 Hyg-P10 TCGGCAGGATATCTTGACGGTTGT 31 PKS4-P6GTCCCGCCGGCTGTAAGGTG 32 Hyg-P13 AGCCCCTGGGTTCGCAAAGATAAT 33 PKS4-P7GCGAGCGAGAGCGACCTGGAT 34 PKS4-P8 ACAACTTCTCCGCTGCTGGTGGTAA 35 PKS4-P1GGCTTTGGGCGCATACCGAGAG 36 PKS4-P4 GCTTCCTCCTGCTGCCAACACTC 37 MPD1-P1GACCCGCCGCTCTTTGACCTACAG 38 MPD1-P4 TTGTGGGGCTTTGGAATCTGTGGA 39 Hyg-P1AGCTGCGCCGATGGTTTCTACAA 40 Hyg-P2 CTGGGGCGTCGGTTTCCACTATC 41 Ura3-P1GibGTCACGACGTTGTAAAACGACGGCCAGTGCCGCCGC 42 GTGCTTCCGTAGA Ura3-P5GibGGTGCGTTGATGGTGCTGATCCTCTTCCTGGATACA 43 TCGGCCGAAACACAG Ura3-P4GibCACACAGGAAACAGCTATGACCATGATTACGGTAGG 44 CGTATGCTGGTGGTGTTGG Ura3-P6GibGGAAGAGGATCAGCACCATCAACGCACCGAGCAGCG 45 CGGGTAATTTGATGAC Ura3-P1CGCCGCGTGCTTCCGTAGA 46 Ura3-P4 GTAGGCGTATGCTGGTGGTGTTGG 47 Ura3-P7TGGGGTGAGGGAAAGAGAAGGACA 48 Ura3-P8 CGCTCAAAGGGCAAACATCAAAGA 49Mdh1-P1Gib GTCACGACGTTGTAAAACGACGGCCAGTGCTGCGGA 50 GCCAACACCCAGATAGMdh1-P2Gib GAACTTGTCCTTCTCTTTCCCTCACCCCAGGAAGCC 51 ACCGACACCAATGTGMdh1-P3Gib GGATCTTTGATGTTTGCCCTTTGAGCGACTTCCGCC 52 GTCTCTGTTTCGTCMdh1-P4Gib CACACAGGAAACAGCTATGACCATGATTACGGAGGC 53 TGAGGACAAGGCAAGAGATMdh1-P1 TGCGGAGCCAACACCCAGATAG 54 Ura3-P13 CACGGCGGTATTGAGCGAGGTAA 55Mdh-P4 GAGGCTGAGGACAAGGCAAGAGAT 56 Ura3-P15 GCCGCAAAGCAGACGAACCT 57Mdh2-P1Gib GTCACGACGTTGTAAAACGACGGCCAGTGCGAGTGG 58 GCGGAGTTGGCGATAGMdh2-P2Gib GAACTTGTCCTTCTCTTTCCCTCACCCCAAGCGGCC 59 TCAATACCCATACCACMdh2-P3Gib GGATCTTTGATGTTTGCCCTTTGAGCGCTCTGACGC 60 CTCCACCTACACCACMdh2-P4Gib CACACAGGAAACAGCTATGACCATGATTACGTTCAC 61 CCTTCGCCCAAACTGCMdh2-P1 GAGTGGGCGGAGTTGGCGATAG 62 Mdh2-P2 TTCACCCTTCGCCCAAACTGC 63

Example 2

MPD1 Disruption Cassette/Strain Construction

A MPD1 (SEQ ID NO. 1) disruption plasmid was constructed by Gibsonassembly using the following PCR fragments: (1) pUC18 amplified withprimers pUC18-P1 and pUC18-P1, (2) MPD1 5′ region amplified with primersMPD-P1 Gib and MPD-P2Gib, (3) MPD1 3′ region amplified with primersMPD-P3Gib and MPD-P4Gib, and (4) the 2.5 kb hygromycin resistancecassette previously amplified with primers TEF-Hyg-P1 and TEF-Hyg-P2(FIG. 3) (See, Table 1 for primer sequences). The resultant plasmidserved as template for PCR amplification of the overlapping split markerregions using primer combinations, a) MPD1-P1 and Hyg-P2; and b) MPD1-P4and Hyg-P1. The resulting PCR product formed the MPD knockout cassette(SEQ ID NO. 6). The DNA fragments were purified by column separation orethanol precipitation; and then used in equimolar amounts fortransformation of A. pullulans NRRL 50384. Transformation was carriedusing electroporation as previously described (Varma, et al., Infect.Immun., 60(3):1101-8 (1992)) using logarithmically growing cells. Afterelectroporation, cells were recovered for 3 hr in YPD medium (1% YE, 2%peptone, 2% glucose) prior to plating on YPD-Hyg plates containing 100μg/ml hygromycin B.

Isolates were transferred at least two times on YPD-Hyg plates and thenscreened by PCR amplification to confirm the following integrationpatterns: (1) deletion of the native mpd1 gene using primers Mpd-P5 andMpd-P6, (2) 5′ cross-over integration of the transforming DNA usingMpd-P7 and Hyg-P11, and (3) 3′ cross-over integration of thetransforming DNA using Mpd-P8 and Hyg P13 (See, Table 1 for primersequences). Primers Mpd-P7 and Mpd-P8 both anneal outside of thehomologous regions of the transforming DNA so PCR amplification asdescribed is persuasive evidence of gene replacement as designed.

Example 3

The isolated MPD1 knock-out (MpdKO) transformants and parent strain A.pullulans NRRL 50384 were grown overnight in complex medium supplementedwith either 50 g/L glucose or 50 g/L fructose. Cells were thenharvested, lysed by shaking with 0.5 mM zirconia/glass beads, andcentrifuged to produce cell-free lysate. These lysates were thenanalyzed for mannitol, arabitol, glycerol, and trehalose content by HPCLusing an Aminex HPX-87H column and refractive index for detection. Allpolyol and trehalose concentrations were normalized against the proteincontent to normalize for discrepancies in lysis efficiency. The MpdKOstrain produced approximately 12× less intracellular mannitol comparedwith A. pullulans NRRL 50384 when grown on glucose. The results areshown in Table 2, where standard deviations are in parentheses andvalues with statistically different values compared with NRRL 50384controls grown under the same condition are marked with asterisks(p<0.05 with T-Test). Under these same conditions, there was almost a2-fold increase in glycerol and 35% increase in trehalose for the MpdKOstrain compared with the parent isolate. However, there was not anystatistical difference in the amount of intracellular arabitol with thisgroup. When this same strain were grown with fructose, there was not anystatistical difference for the intracellular polyols and trehalosebetween the NRRL 50384 and MpdKO strain, but there were largedifferences in relative amounts compared with NRRL 50384 grown inglucose. Most notable was the 4-fold increase in mannitol for NRRL 50384when grown in fructose containing medium. It is assumed the increasedmannitol is due to fructose being converted directly into mannitolthrough a Mdh2-mediated reaction. This reaction would explain why theMpdKO strain did not exhibit decreased mannitol when grown withfructose, since Mpd1 protein would not be involved in this pathway (FIG.2).

TABLE 2 Polyol and Trehalose Accumulation in WT and MpdKO strains.Relative intracellular concentrations Strain/carbon source MannitolArabitol Glycerol Trehalose 50384/glucose 0.660 (0.020) 0.127 (0.021)0.062 (0.001) 2.070 (0.022) MpdKO/glucose  0.055 (0.014)* 0.109 (0.011) 0.112 (0.015)*  2.801 (0.156)* 50384/Fructose 2.768 (0.046) 0.012(0.021) 0.038 (0.016) 0.323 (0.008) MpdKO/fructose 2.7196 (0.107)  0.028(0.010) 0.028 (0.010) 0.323 (0.010)

Example 4 ((MpdKO Strain, Liamocin Analysis))

To analyze whether deletion of the MPD1 gene shifted bioproductproduction in genetically altered A. pullulans strains, liamocins wereproduced and purified as previously described (Manitchotpisit, 2011,ibid.) from cultures grown with 50 g/L glucose, the MpdKO strainproduced nearly 100% arabitol-containing liamocins compared to 100%mannitol-containing liamocins for NRRL 50384 (FIG. 4). Under theseconditions, there was only a 15% decrease in yield compared with thewildtype, demonstrating that the robustness and productivity of thisstrain were minimally affected. When grown with 50 g/L fructose, therewas not any statistical difference in liamocin yield and molecularstructures between the parent and MpdKO strains (FIG. 5). It is assumedthat the formation of mannitol-containing liamocins under theseconditions is a result of the high amount of mannitol, presumably frommannitol dehydrogenase (the protein encoded by MDH2) conversion offructose, and the relatively lower amount of arabitol.

Example 5

PKS Disruption Cassette/Strain Construction

A PKS4 disruption plasmid was constructed by Gibson assembly using thefollowing PCR fragments: (1) pUC18 amplified with primers pUC18-P1 andpUC18-P1, (2) PKS4 5′ region amplified with primers PKS4-P1Gib andPKS4-P2Gib, (3) PKS4 3′ region amplified with primers PKS4-P3Gib andPKS4-P4Gib, and (4) the 2.5 kb hygromycin resistance cassette previouslyamplified with primers TEF-Hyg-P1 and TEF-Hyg-P2 (FIG. 3) (See, Table 1for primer sequences). The resultant plasmid served as template for PCRamplification of the overlapping split marker regions using primercombinations, a) PKS4-P1 and Hyg-P2; and b) PKS4-P4 and Hyg-P1 (See,Table 1 for primer sequences). The resulting PCR product formed the PKSknockout cassette (SEQ ID NO. 7). The DNA fragments were purified bycolumn separation or ethanol precipitation; and then used in equimolaramounts for transformation of A. pullulans NRRL 50384. Transformationwas carried using electroporation as previously described (Varma, etal., Infect. Immun., 60(3):1101-8 (1992)) using logarithmically growingcells. After electroporation, cells were recovered for 3 hr in YPDmedium (1% YE, 2% peptone, 2% glucose) prior to plating on YPD-Hygplates containing 100 μg/ml hygromycin B.

Isolates were transferred at least two times on YPD-Hyg plates and thenscreened by PCR amplification to confirm the following integrationpatterns: (1) 5′ cross-over integration of the transforming DNA usingPKS4-P5 and Hyg-P10, (2) 3′ cross-over integration of the transformingDNA using PKS4-P6 and Hyg P13, and (3) deletion of the native pks4 geneusing primers PKS4-P7 and PKS4-P8 (See, Table 1 for primer sequences).Primers PKS4-P5 and PKS4-P6 both anneal outside of the homologousregions of the transforming DNA so PCR amplification as described ispersuasive evidence of gene replacement as designed.

Isolates were transferred at least two times on selective medium andthen screened for PCR amplification of the 5′ and 3′ integrationjunctions; and deletion of the native gene, which would only occur withintegration of the constructed DNA fragment. Confirmed deletion isolateswere chosen for further analyses. The resulting strain lacking afunctional PKS4 gene was termed PksKO.

Example 6

To determine whether a PksKO strain was capable of producing a desiredbioproduct (liamocins) without melanin contamination, liamocins wereproduced and purified as previously described (Manitchotpisit, 2011,ibid.). NRRL 50384 and PksKO strains were utilized for this analysis.Cultures were grown with 50 g/L sucrose, the isolated knock-out (KO)transformant had no melanin-pigment accumulation in the cultures (FIG.6) and the final product had superior clarity (FIG. 7). There was notany statistical difference in liamocin yield (data not shown) and themolecular structures (FIG. 8) were the same between the parent and KOstrains.

Example 7

Deleting multiple genes in A. pullulans is more convenient with theavailability of multiple selectable markers, so we created a ura3auxotroph in A. pullulans. Using the sequenced genome of A. pullulansNRRL 50384, we identified an orotidine 5′phosphate decarboxylase genethat was homologus to another previously described ura3 gene. A Ura3disruption plasmid was constructed by Gibson assembly using thefollowing PCR fragments: (1) pUC18 amplified with primers pUC18-P1 andpUC18-P1, (2) Ura3 5′ region amplified with primers Ura3-P1Gib andUra3-P5Gib using A. pullulans NRRL 50384 DNA as template, and (3) Ura33′ region amplified with primers Ura3-P4Gib and Ura4-P6Gib using A.pullulans NRRL 50384 DNA as template. The resultant plasmid served as atemplate for PCR amplification using primers Ura3-P1 and Ura3-P4. TheDNA fragment were purified by column separation or ethanolprecipitation; and then used for transformation of A. pullulans NRRL50384. Transformation was carried using electroporation as previouslydescribed using logarithmically growing cells. After electroporation,cells were transferred to yeast nitrogen base without amino acids (YNB,Difco) supplemented with 2% glucose and 50 mg/L uracil, and 1 mg/ml5-fluoroorotic (FOA) acid for selection of uracil auxotrophs. Isolateswere transferred at least two times on YNB-FOA plates and then screenedon YNB with and without uracil. All of the recovered isolates wereconfirmed uracil auxotrophs with mutations in the ura3 gene. We furtherestablished that at least one of the isolates, A. pullulans B44p41-01,could be restored to uracil prototrophy by transformation with a ura3DNA fragment obtained from PCR amplification using primers Ura3-P7 andUra-P8.

Example 8

Using the sequenced genome of A. pullulans NRRL 50384, we identified twoMDH genes that are likely involved in conversion between mannitol andfructose. We deleted the first of these genes, termed “MDH1”. A MDH1disruption plasmid was constructed by Gibson assembly using thefollowing PCR fragments: (1) pUC18 was amplified with primers pUC18-P1and pUC18-P1, (2) MDH1 5′ region was amplified with primers Mdh1-P1Giband Mdh1-P2Gib, (3) MDH1 3′ region was amplified with primers Mdh1-P3Giband Mdh1-P4Gib, and (4) the 2.5 kb ura3 cassette previously amplifiedwith primers Ura3-P7 and Ura3-P8 (See, Table 1 for primer sequences).The resultant plasmid served as template for PCR amplification of theoverlapping split marker regions using primer combinations, a) Mdh1-P1and Ura3-P13; and b) Mdh1-P4 and Ura3-P15 (See, Table 1 for primersequences). The DNA fragments were purified by column separation orethanol precipitation; and then used in equimolar amounts fortransformation of A. pullulans NRRL 50384. Transformants with confirmedintegration and deletion of the mdh1 gene, as indicated by PCRamplification, were then used as a recipient strain for transformationwith the overlapping MPD1-Hyg fragments as described above. Resultingknockout strains were analyzed for intracellular polyols, as previouslydescribed. The results show that neither A. pullulans (mdh1) nor A.pullulans (mdh1, mpd1) had significant differences in intracellularmannitol, arabitol, glycerol, and trehalose compared with A. pullulansNRRL 50384. However, both mdh1 deletion strains were incapable of growthin YNB (2% mannitol), while A. pullulans NRRL 50384 and A. pullulans(mpd1) were able to achieve OD600>8.0 after 48 hrs.

Example 9

Deletion of the second putative MDH-encoding gene (termed “MDH2”) thatwas identified can be achieved using the same scheme as outlined above.The resulting strain is termed Mdh2KO. A MDH2 disruption plasmid isconstructed by Gibson assembly using the following PCR fragments: (1)pUC18 amplified with primers pUC18-P1 and pUC18-P1, (2) MDH2 5′ regionamplified with primers Mdh2-P1Gib and Mdh2-P2Gib, (3) MDH2 3′ regionamplified with primers Mdh2-P3Gib and Mdh2-P4Gib, and (4) the 2.5 kbura3 cassette previously amplified with primers Ura3-P7 and Ura3-P8(See, Table 1 for primer sequences). The resultant plasmid serves astemplate for PCR amplification of the overlapping split marker regionsusing primer combinations, a) Mdh2-P1 and Ura3-P13; and b) Mdh2-P4 andUra3-P15. The DNA fragments are purified by column separation or ethanolprecipitation; and then used in equimolar amounts for transformation ofA. pullulans NRRL 50384.

To analyze whether deletion of the MDH2 gene shifted bioproductproduction in genetically altered A. pullulans strains, liamocins areproduced, purified and analyzed as previously described (Manitchotpisit,2011, ibid.). Transformant A. pullulans (mdh2) served as a recipientstrain for further deletion of mpd1 as described in Example 2. Culturesof A. pullulans (mdh2), A. pullulans (mdh2, mpd1) and A. pullulans NRRL50384 were grown in the presence of 50 g/L glucose or 50 g/L fructoseand differences in intracellular mannitol, arabitol, glycerol,trehalose, and fructose are analyzed as described in Example 3, but areexpressed based on cell dry weight in Table 3, where standard deviationsare in parentheses and quantities with statistically different valuescompared with NRRL 50384 controls grown under the same conditions aremarked with asterisks (p<0.05 with T-Test).

TABLE 3 Polyol and fructose accumulation in WT, Mdh2KO, and Mdh2.Mpd1KOstrains Intracellular concentrations (μg/mg cell dry weight)Strain/carbon source Mannitol Arabitol Glycerol Trehalose Fructose50384/glucose 67.1 (5.3) 5.0 (0.9) 2.7 (0.1) 125.7 (6.5)  0Mdh2KO/glucose 66.9 (3.9) 3.8 (0.1) 2.7 (0.1) 117.0 (2.5)  0Mdh2KO/Mpd1KO/glucose 0* 3.0 (0.4)  5.8 (0.2)* 181.7 (8.8)* 050384/fructose 147.8 (8.4)  0.7 (1.0) 2.0 (0.6) 17.2 (0.8)  80.8 (26.3)Mdh2KO/fructose 102.2 (3.5)* 0.5 (0.0) 3.3 (0.1)  54.6 (2.7)* 37.9 (3.2)Mdh2KO/Mpd1KO/fructose  6.1 (0.2)*  1.7 (0.1)*  6.8 (0.1)*  99.6 (1.8)*61.0 (1.5)

There was not any significant decrease in mannitol for the Mdh2KO straincompared with the parent isolate when grown on glucose. However, theMdh2KO/Mpd1KO strain did not have any detectable mannitol under thesesame conditions. Arabitol was only slightly less for the two modifiedstrains, but the Mdh2KO/Mpd1KO strain had more than 2-fold increase inglycerol and nearly 50% increase in trehalose compared with the parentstrain. The Mdh2KO strain did not show any difference in the levels ofthese compounds compared with the parent strain under these conditions.

When grown on fructose, there was a slight decrease in the mannitol forthe Mdh2KO strain compared with the parent isolate, while theMdh2KO/Mpd1KO strain had more than 95% less mannitol compared with thecontrol. Under these same conditions, the Mdh2KO/Mpd1KO strain also hadsignificantly higher concentrations of arabitol, glycerol, and trehalosecompared with the parent strain. The Mdh2KO strain had significantlyhigher trehalose compared with the control.

Further analysis of these cultures revealed that the Mdh2KO strainproduced nearly 100% mannitol-containing liamocin (FIGS. 10 and 11) withboth glucose and fructose in a similar manner as the parent strain(FIGS. 4 and 5). The Mdh2KO/Mpd1KO strain produced significant amountsof arabitol-containing liamocin with glucose (FIG. 10), but exophilins(i.e., liamocin without a polyol or carbohydrate headgroup) appeared tobe the predominant structure under these conditions. The Mdh2KO/Mpd1KOstrain grown with fructose also appeared to have a predominance ofexophilins, but also contained significant amounts of a surprisinglyunique structure containing fructose as a headgroup (FIG. 11). Theassignment of the fructose head group was further confirmed byhydrolyzing liamocin samples using 2M TFA (80° C., 1 hr), partitioningwith aqueous chloroform to remove the released fatty acids, andperacetylating the released fructose in the aqueous layer (using aceticanhydride, pyridine 1:1 v/v, 80° C., 30 min). The peracetylatedheadgroup components were analyzed by gas chromatography (FIG. 12), andthe structural assignment of the peracetylated fructose was confirmed byGC/MS. The structure of these fructose-type liamocins has not beenpreviously described and has never been observed to be formed by WTstrains.

Example 10

As another example, we report on the simplified purification of massoialactone from A. pullulans strain PksKO. In analyzing the PksKO strain,we discovered that this strain produced massoia lactone, a bioproductnever before identified as produced by A. pullulans. However, selectiveextraction of the cultures of the Aureobasidium PksKO strain withbutan-2-one followed by butan-2-one:chloroform:water (1:2:2 by volume)partitioning recovered a product identical to massoia lactone (1H-NMR,13C-NMR, COSY, HSQC, HMBC, and MALDI-TOF MS analyses. 13C-NMR chemicalshifts (in CDCl3): C1 C═O, 165.46 ppm; C2 CH, 121.26 ppm; C3 CH, 145.61ppm; C4 CH2, 29.36 ppm; C5 CH 78.31 ppm; C6 CH2, 34.76 ppm; C7 CH2,24.45 ppm; C8 CH2, 31.50 ppm; C9 CH2, 22.47 ppm; C10 CH3, 13.94 ppm.M=m/z 168; [M=Na]+=m/z 191. The massoia lactone was of high purity (FIG.9), and the NMR data was obtained without the need for chromatographyclean-up. Determination of yield can be determined gravimetrically usingA. pullulans PksKO. Purification of liamocins will be as previouslydescribed, followed by butan-2-one:chloroform:water (1:2:2 by volume)partitioning to recover massoia lactone.

What is claimed is:
 1. A method of producing arabitol-liamocins,comprising the steps of a) growing a culture of Aureobasidium pullulanslacking a functional mannitol-1-phosphate-dehydrogenase (MPD1) geneunder conditions sufficient to support the production ofarabitol-liamocins, wherein said conditions comprise the substantialabsence of arabitol; and b) collecting said arabitol-liamocins from atleast part of said culture, thereby producing arabitol-liamocins.
 2. Themethod of claim 1, wherein the biologically pure strain comprises NRRL67079.
 3. The method of claim 1, wherein said conditions furthercomprise a growth medium containing glucose as the sole carbon source.4. A method of producing one or more bioproducts, comprising the stepsof a) growing a culture of Aureobasidium pullulans lacking a functionalmannitol-dehydrogenase (MDH2) gene and lacking a functionalmannitol-1-phosphate-dehydrogenase (MPD1) gene under conditionssufficient to support the production of one or more bioproducts selectedfrom the group consisting of a liamocin and an exophilin; and b)collecting said one or more bioproducts from at least part of saidculture, thereby producing the bioproduct.
 5. The method of claim 4,wherein said conditions comprise a growth medium containing glucose orfructose as the sole carbon source.
 6. The method of claim 4, whereinthe bioproduct is an exophilin.
 7. The method of claim 4, wherein thebioproduct is a liamocin and wherein said liamocin has a head groupcomprising lactose, glucose, mannose, galactose, arabinose, xylose,glucitol, galactitol, xylitol, ribitol, threitol, erythritol, orglycerol.
 8. The method of claim 4, wherein the bioproduct is afructose-liamocin.